![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Publication history |
Reprints |
Permissions |
Cite this article as |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
Minerva Surgery 2022 Mar 01
DOI: 10.23736/S2724-5691.22.09284-X
Copyright © 2022 EDIZIONI MINERVA MEDICA
language: English
Outcome and risk factors for local recurrence after breast conserving surgery in patients affected by ductal carcinoma in situ
Giovanni TOMASICCHIO 1 ✉, Arcangelo PICCIARIELLO 1, Luigia S. STUCCI 2, Annunziata PANEBIANCO 1, Alda E. MONTANARO 3, Alfredo CIRILLI 3, Clelia PUNZO 1
1 Division of Surgery, Department of Emergency and Organ Transplant (DETO), University Aldo Moro of Bari, Bari, Italy; 2 Medical Oncology Unit, Policlinico Hospital, Bari, Italy; 3 Breast Unit Surgery, Policlinico Hospital, Bari, Italy
BACKGROUND: Ductal carcinoma in situ (DCIS) is a tumour with long term survival and low local recurrence rate. Although the progression of these lesions is rare, the current guidelines recommend breast conservating surgery (BCS) with adjuvant radio and/or endocrine therapy, often resulting in an overtreatment for patients. The aim of this single-centre study is to evaluate the long-term outcome of the breast conservating surgery of DCIS followed by adjuvant radio and/or endocrine therapy and to identify prognostic factors associated with the risk of recurrence.
METHODS: Patients treated for DCIS with BCS and radiation therapy between March 2006 and January 2019 were retrospectively reviewed using a prospectively maintained database. Analysis of the potential risk factors was performed to evaluate the risk of subsequent ipsilateral and contralateral recurrence.
RESULTS: Out of 2894 patients, two hundred eighty-eight (10%) patients were treated for DCIS. After a median follow-up of 85 months (IQR 27-124), the incidence of recurrence was 6% (18 patients). Nine of them (3%) had an ipsilateral local recurrence (LR) with a median disease-free survival of 19 months (IQR 12-35). The remaining nine patients had contralateral metachronous breast cancer (CBC) with a median DFS of 29 months (IQR 14-36). Margin status, multifocality, hormone receptor status and Her-2/Basal-like subtype were identified as risk factors for the local recurrence with a OR of 5.58 (1.44-21.54), 7.46(1.89-24.48) 0.25 (0.06-0.96) and 4.86 (1.26-18.71) respectively.
CONCLUSIONS: DCIS had been confirmed to have long term survival. Margin status, multifocality, hormone receptor status and Her-2/Basal-like subtype could be identified as reliable risk factors for the progression of the disease.
KEY WORDS: Ductal carcinoma in situ; Breast cancer; Follow-up; Prognostic factors